Redeye comments on Hansa Biopharma's Q3 report, published yesterday, a quarter of execution in which the company received the EUR110m SERB upfront, prepaid part of the NovaQuest debt and finished most of its US pre-launch work. With cash of SEK1.3bn and the commercial infrastructure largely in place, the FDA's decision on December 19 is a major catalyst. We lower our base case to SEK75 (SEK85), mainly because we remove the Sarepta gene therapy milestones.
LÄS MER
